RPGLIFE · RPG Life Sciences Ltd · Biotechnology & Drugs
RPGLIFE · RPG Life Sciences Ltd · Biotechnology & Drugs
As of 05 Nov close
52-week range
17.0% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 51 days old
Revenue (latest Q)
₹196 Cr
Revenue YoY
PAT YoY
+17.0%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
7.4
P/S (TTM)
6.1
Sector P/E
36.3
Dividend yield
+0.9%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| RPGLIFE (this stock) | 31.7 | 7.4 | +16.3% | +19.8% | 0.03 | +0.9% |
| Sun Pharmaceutical Industries | 38.4 | 5.6 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 72.7 | 19.2 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
rising 1q
MF
0.04% (0.00pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| RPGLIFE | 2026-05-01 | 109801 | 1 | WEAK | BULK |
| RPGLIFE | 2026-04-30 | 109801 | 1 | WEAK | BULK |
News timeline
- lowlivemint.com· 06 Sept 2026, 05:49 pmRPG Life Sciences bets on China-plus 1, goes on an API buying spree
Concalls & investor presentations
AI-generatedKey takeaway: The investor presentation dated September 2, 2026, outlines strategic developments for RPG Life Sciences Limited (RPGLIFE). The API business has been transferred to a new subsidiary, RPGAP, through a slump sale, with 100% ownership by RPGAP. RPGAP has partnered with InvAscent, a pharma-focused private equity firm, with InvAscent acquiring a 40% stake via primary issuance for ~243.33 Cr INR. RPGAP also acquired Actis Generics for ~80 Cr INR, a fully integrated API manufacturer in Vizag, and Raghava Life Sciences via slump sale for ~135 Cr INR, adding manufacturing capacity and R&D capabilities. The presentation highlights RPGAP's strategic focus on API, enhanced product portfolios, and growth through partnerships and acquisitions. Management emphasized operational strengths, including state-of-the-art facilities, R&D initiatives, and long-term customer relationships, alongside financial prudence with zero debt and sufficient liquidity for future growth.
The presentation emphasizes strategic advancements, partnerships, and operational strengths with no mention of challenges or risks.
Sourced from an exchange-filed presentation, dated 02 Sept 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: RPG Life Sciences Limited submitted an investor presentation detailing its unaudited financial results for the quarter ended June 30, 2026. The presentation highlighted a robust performance with a 15.8% increase in revenue and a 17.0% growth in profit after tax (PAT) compared to the same quarter in the previous year. The domestic formulations segment contributed 68.3% to total sales, driven by new product launches in specialty and chronic segments. The API segment faced challenges due to a fire incident but continued to focus on new customer development. The company reaffirmed its A+ long-term rating and A1 short-term rating, citing strong brands and a healthy capital structure. Additionally, RPG Life Sciences received three industry awards for its innovations and effectiveness in sales force management. The presentation outlined seven strategic pillars for future growth, including portfolio development and digital initiatives.
Management emphasized strong financial performance and strategic growth initiatives.
Sourced from an exchange-filed presentation, dated 28 Jul 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: RPG Life Sciences Limited submitted an investor presentation for the RPG Annual Investor Conference 2026, scheduled for May 26, 2026. The presentation highlighted the company's operations in the pharmaceutical sector, focusing on branded formulations, global generics, and synthetic APIs. Management reported a revenue of ₹707.5 crore for FY26, reflecting an 8.3% growth compared to FY25, with a strong EBITDA of ₹172.7 crore, representing a 24.4% margin. The company emphasized its consistent outperformance in the domestic formulations segment, which contributed 69% of sales, and noted a significant increase in market position, ranking 52nd in the Indian Pharma Market. Additionally, management outlined strategies for growth, including enhancing manufacturing capabilities and focusing on high-growth therapy areas. The presentation also addressed the company's commitment to environmental sustainability, reporting reductions in carbon emissions and hazardous waste.
Management emphasized strong financial performance and growth strategies.
Sourced from an exchange-filed presentation, dated 25 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The earnings call transcript for RPG Life Sciences Limited, held on April 30, 2026, at 3:30 p.m. IST, was made available on the company's website. This call discussed the audited financial results for the quarter and year ended March 31, 2026. The company communicated this information in a letter dated May 8, 2026, to the National Stock Exchange of India and BSE Limited, requesting that the information be recorded and disseminated appropriately. Rajesh Shirambekar, the Head of Legal & Company Secretary, signed the letter digitally.
The document presented factual information regarding the earnings call and its availability.
Sourced from an exchange-filed transcript, dated 08 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: The investor presentation from RPG Life Sciences Limited detailed the company's audited financial results for the quarter ending March 31, 2026. Management reported a robust performance with a 23.6% increase in revenue and a 58.1% growth in profit after tax (PAT), excluding exceptional items. The presentation highlighted RPG Life Sciences' integrated pharmaceutical operations, emphasizing its leadership in immunosuppressants and a diverse product portfolio across various therapeutic areas. The company outlined its strategic priorities, including scaling core brands, expanding its global presence, and enhancing manufacturing capabilities. Additionally, management noted improvements in operational efficiency and a commitment to environmental, social, and governance (ESG) initiatives. The document also reaffirmed the company's strong credit ratings, reflecting its solid financial health and growth prospects.
Management emphasized strong financial performance and strategic growth initiatives.
Sourced from an exchange-filed presentation, dated 30 Apr 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedRPG Life Sciences Limited (RPGLIFE) reported no significant audit issues, defaults, or regulatory penalties in FY2025-26. The company made a ₹34.77 crore investment in its subsidiary RPG Active Pharma Limited. No related-party transactions at non-arm’s length were disclosed, and no material changes affected its financial position. The statutory auditors did not issue any adverse remarks, and there were no defaults in loan repayments or regulatory actions impacting its going-concern status. The company maintains robust risk management frameworks and complies with corporate governance standards.
- No adverse audit opinions or regulatory penalties noted.
- Invested ₹34.77 crore in wholly-owned subsidiary RPG Active Pharma Limited.
- No defaults in loan repayments or regulatory actions impacting operations.
- No material changes affecting financial position between FY2025-26 and report date.
Key takeaway: RPG Life Sciences Limited reported a clean audit with no significant financial or regulatory issues, maintained compliance, and made strategic investments in its subsidiary, indicating stable operations and adherence to governance standards.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Contingent Liability
3 occurrencesRecent (last 12 months)
The company has margin money deposits of ₹10 lakhs with Maharashtra Pollution Control Board and ₹2 lakhs with Raksha Mantralaya Karyalaya as part of compliance with conditions for pollution control devices, as of 31 March 2025.
Earlier (1-3 years ago)
The company has margin money deposits of ₹10 lakhs with Maharashtra Pollution Control Board and ₹2 lakhs with Raksha Mantralaya Karyalaya as security for bank guarantees related to pollution control compliance.
The company has margin money deposits of Rs 10 lakhs with Maharashtra Pollution Control Board and Rs 2 lakhs with Raksha Mantralaya Karyalaya as security for bank guarantees.
Statutory dues in dispute
3 occurrencesRecent (last 12 months)
The company has outstanding statutory dues under various acts, including Goods and Services Tax, Excise duty, and Sales Tax, with amounts pending before appellate authorities for periods ranging from 1997-1998 to 2021-22.
Earlier (1-3 years ago)
The company has pending tax disputes under the Gujarat Sales Tax Act, 1969 and The Finance Act, 1994, with amounts relating to periods from 1997-1998 to 2000-2001 and April 2006 to May, respectively.
The company has outstanding statutory dues under various acts, including Gujarat Sales Tax Act, The Finance Act, 1994, and The Central Excise Act, with amounts pending before different appellate authorities.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
3.19% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).